Literature DB >> 27444043

Precision treatment with sirolimus in a case of activated phosphoinositide 3-kinase δ syndrome.

William Rae1, Kesava A Ramakrishnan2, Yifang Gao3, Margaret Ashton-Key4, Reuben J Pengelly5, Sanjay V Patel6, Sarah Ennis5, Anthony P Williams7, Saul N Faust2.   

Abstract

Entities:  

Keywords:  Activated phosphoinositide 3-kinase δ syndrome; Autoimmune hemolytic anemia; Sirolimus

Mesh：

Substances：

Year:  2016        PMID： 27444043     DOI： 10.1016/j.clim.2016.07.017

Source DB:  PubMed          Journal:  Clin Immunol        ISSN： 1521-6616            Impact factor:   3.969


× No keyword cloud information.
  11 in total

Review 1.  Immune Dysregulation and Disease Pathogenesis due to Activating Mutations in PIK3CD-the Goldilocks' Effect.

Authors:  Stuart G Tangye; Julia Bier; Anthony Lau; Tina Nguyen; Gulbu Uzel; Elissa K Deenick
Journal:  J Clin Immunol       Date:  2019-03-25       Impact factor: 8.317

2.  Persistent Impairment of T-Cell Regeneration in a Patient with Activated PI3K δ Syndrome.

Authors:  Fumihiro Goto; Toru Uchiyama; Yumiko Nakazawa; Kohsuke Imai; Toshinao Kawai; Masafumi Onodera
Journal:  J Clin Immunol       Date:  2017-04-21       Impact factor: 8.317

Review 3.  Phosphoinositide-3-Kinase Signaling in Human Natural Killer Cells: New Insights from Primary Immunodeficiency.

Authors:  Emily M Mace
Journal:  Front Immunol       Date:  2018-03-07       Impact factor: 7.561

4.  Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.

Authors:  Maria Elena Maccari; Hassan Abolhassani; Asghar Aghamohammadi; Alessandro Aiuti; Olga Aleinikova; Catherine Bangs; Safa Baris; Federica Barzaghi; Helen Baxendale; Matthew Buckland; Siobhan O Burns; Caterina Cancrini; Andrew Cant; Pascal Cathébras; Marina Cavazzana; Anita Chandra; Francesca Conti; Tanya Coulter; Lisa A Devlin; J David M Edgar; Saul Faust; Alain Fischer; Marina Garcia-Prat; Lennart Hammarström; Maximilian Heeg; Stephen Jolles; Elif Karakoc-Aydiner; Gerhard Kindle; Ayca Kiykim; Dinakantha Kumararatne; Bodo Grimbacher; Hilary Longhurst; Nizar Mahlaoui; Tomas Milota; Fernando Moreira; Despina Moshous; Anna Mukhina; Olaf Neth; Benedicte Neven; Alexandra Nieters; Peter Olbrich; Ahmet Ozen; Jana Pachlopnik Schmid; Capucine Picard; Seraina Prader; William Rae; Janine Reichenbach; Stephan Rusch; Sinisa Savic; Alessia Scarselli; Raphael Scheible; Anna Sediva; Svetlana O Sharapova; Anna Shcherbina; Mary Slatter; Pere Soler-Palacin; Aurelie Stanislas; Felipe Suarez; Francesca Tucci; Annette Uhlmann; Joris van Montfrans; Klaus Warnatz; Anthony Peter Williams; Phil Wood; Sven Kracker; Alison Mary Condliffe; Stephan Ehl
Journal:  Front Immunol       Date:  2018-03-16       Impact factor: 7.561

Review 5.  Bacille Calmette-Guerin Complications in Newly Described Primary Immunodeficiency Diseases: 2010-2017.

Authors:  Cristiane de Jesus Nunes-Santos; Sergio D Rosenzweig
Journal:  Front Immunol       Date:  2018-06-22       Impact factor: 7.561

Review 6.  Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8+ T Cell Survival, Differentiation, and Function.

Authors:  Jennifer L Cannons; Silvia Preite; Senta M Kapnick; Gulbu Uzel; Pamela L Schwartzberg
Journal:  Front Immunol       Date:  2018-08-02       Impact factor: 7.561

Review 7.  PI3Kδ and primary immunodeficiencies.

Authors:  Carrie L Lucas; Anita Chandra; Sergey Nejentsev; Alison M Condliffe; Klaus Okkenhaug
Journal:  Nat Rev Immunol       Date:  2016-09-12       Impact factor: 53.106

Review 8.  Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency.

Authors:  Jean-Marie Carpier; Carrie L Lucas
Journal:  Front Immunol       Date:  2018-01-16       Impact factor: 7.561

Review 9.  "Immune TOR-opathies," a Novel Disease Entity in Clinical Immunology.

Authors:  Sophie Jung; Laura Gámez-Díaz; Michele Proietti; Bodo Grimbacher
Journal:  Front Immunol       Date:  2018-05-09       Impact factor: 7.561

10.  Successful Sirolimus Treatment for Korean Patients with Activated Phosphoinositide 3-kinase δ Syndrome 1: the First Case Series in Korea.

Authors:  Ji Man Kang; Su Kyung Kim; Dongsub Kim; Sae Rom Choi; Yeon Jung Lim; Soon Ki Kim; Byung Kiu Park; Weon Seo Park; Eun Suk Kang; Young Hyeh Ko; Yon Ho Choe; Ji Won Lee; Yae Jean Kim
Journal:  Yonsei Med J       Date:  2020-06       Impact factor: 2.759
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.